US launch of EKTERLY® gaining strong momentum with $13.7 million in net product revenue for the third quarter 937 patient start forms received through October, reflecting rapid adoption as first and only oral on-demand treatment for hereditary angioedema (HAE) Launched EKTERLY in Germany with initial orders signaling encouraging demand $309M in cash expected to fund the Company through profitability Management to host... Read More

KONFIDENT-S participants who switched to sebetralstat reported being very or extremely satisfied Interim results from KONFIDENT-KID show sebetralstat enables early, effective, safe treatment of HAE attacks in pediatric population and reveal higher attack frequency than previously believed FRAMINGHAM, Mass. & SALISBURY, England / Nov 06, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced new... Read More

FRAMINGHAM, Mass. & SALISBURY, England / Nov 05, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at each of the following upcoming investor conferences: Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at 8:40 a.m. EST Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025, at 1:30 p.m. GMT... Read More

FRAMINGHAM, Mass. & SALISBURY, England / Nov 03, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) will host a conference call and webcast on Tuesday, November 11, 2025, at 8:30 a.m. ET to review the Company’s third quarter financial results and provide an operational update. The live audio webcast will be accessible on the Investors section of the Company’s website at www.ir.kalvista.com/event-calendar.... Read More

FRAMINGHAM, Mass. & SALISBURY, England / Oct 30, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced the acceptance of one abstract for late-breaking oral presentation and three for poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida from November 6–10, 2025. The lake-breaking oral presentation... Read More

Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapies FRAMINGHAM, Mass. & SALISBURY, England / Oct 06, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY ® (sebetralstat), the first and only oral... Read More

FRAMINGHAM, Mass. & SALISBURY, England / Oct 06, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointments of Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, effective October 6, 2025. “I am pleased to welcome Bilal and Linea to our leadership team as we advance the global launch of EKTERLY,” said Ben Palleiko, Chief Executive Officer of KalVista.... Read More

FRAMINGHAM, Mass. & SALISBURY, England / Oct 03, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 30,000 shares of KalVista common stock on October 1, 2025 as inducements material to each employee entering into employment with KalVista. The... Read More

FRAMINGHAM, Mass. & SALISBURY, England / Oct 02, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the appointment of Bethany L. Sensenig to its Board of Directors, effective as of October 1, 2025. Ms. Sensenig was also appointed a member of the Audit Committee of the Board. In connection with Ms. Sensenig’s appointment to the Audit Committee, Nancy Stuart will transition off the Audit... Read More

FRAMINGHAM, Mass. & SALISBURY, England / Sep 26, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced the acceptance of six abstracts for ePoster presentation at the 20 th German Allergy Congress taking place in Düsseldorf, Germany from October 2–4, 2025. Details are as follows: Thursday, October 2 at 4:00–5:15 pm CEST: Time to End of Progression of Hereditary Angioedema Attacks Treated with... Read More

FRAMINGHAM, Mass. & SALISBURY, England / Sep 24, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV), announced today the pricing of its offering of $125.0 million aggregate principal amount of 3.250% Convertible Senior Notes due 2031 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as... Read More

FRAMINGHAM, Mass. & SALISBURY, England / Sep 24, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (“KalVista”) (NASDAQ: KALV) announced today that it intends to offer, subject to market conditions and other factors, $110.0 million aggregate principal amount of Convertible Senior Notes due 2031 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A... Read More

First European launch of EKTERLY expected in Germany Q4 2025 EKTERLY now approved in the US, EU, UK and Switzerland with additional regulatory applications under review in key global markets FRAMINGHAM, Mass. & SALISBURY, England / Sep 19, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced that the European Commission (EC) and Swiss Agency for Therapeutic Products, Swissmedic, have approved... Read More

EKTERLY® now approved in the US and UK; first and only oral on-demand therapy for acute attacks of hereditary angioedema Initiated US EKTERLY launch in July; received 460 patient start forms through August European Medicines Agency adopted a positive opinion recommending approval of sebetralstat and confirmed maintenance of orphan designation in EU; decision expected early October $191M in cash, providing runway into 2027... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Sep 04, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the company will host a live webcast at 8:30 a.m. ET on Thursday, September 11, 2025 to provide an operational update and release financial results for the fiscal quarter ended July 31, 2025. The webcast can be accessed on the Investors section of the Company’s website at Kalvista.com . A... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Sep 04, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 5,000 shares of KalVista common stock on September 1, 2025 as inducements material to each employee entering into employment with KalVista. The... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Aug 27, 2025 / Business Wire / KalVista Pharmaceuticals, Inc . (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 10:55 a.m. ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com . An audio archive will be available on... Read More

Sebetralstat is one of only two hereditary angioedema therapies to maintain orphan designation, underscoring its major contribution to patient care If approved, sebetralstat will be granted 10 years of market exclusivity in EU CAMBRIDGE, Mass. & SALISBURY, England / Aug 11, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced that the Committee for Orphan Medicinal Products (COMP) of the... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Aug 04, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 44,000 shares of KalVista common stock on August 1, 2025 as inducements material to each employee entering into employment with KalVista. The... Read More

If approved, sebetralstat will be the first and only oral on-demand treatment for HAE in the European Union (EU) European Commission decision expected by early October 2025 CAMBRIDGE, Mass. & SALISBURY, England / Jul 25, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a... Read More

EKTERLY to be added to the Orphan Register and awarded 10 years of market exclusivity CAMBRIDGE, Mass. & SALISBURY, England / Jul 15, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has granted marketing authorization for EKTERLY ® (sebetralstat), a novel plasma kallikrein inhibitor, for the... Read More

Received FDA approval of EKTERLY® (sebetralstat)—the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway Six additional global regulatory submissions under review Entered licensing agreements for sebetralstat commercialization in Japan and Canada $220.6M in cash, providing runway into 2027 CAMBRIDGE, Mass. & SALISBURY, England / Jul 10, 2025 / Business Wire / KalVista Pharmaceuticals, Inc.... Read More

First new on-demand HAE treatment in over a decade, with potential to transform management of the disease Data demonstrated rapid symptom relief and attack resolution regardless of attack severity, location, age, or use of long-term prophylaxis, and well-established safety profile Management to host conference call today at 8:30 a.m. ET CAMBRIDGE, Mass. & SALISBURY, England / Jul 07, 2025 / Business Wire / KalVista... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jul 02, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 23,000 shares of KalVista common stock on July 1, 2025 as inducements material to each employee entering into employment with KalVista. The options... Read More

Sebetralstat has potential to become first oral on-demand treatment for HAE in Canada Pendopharm brings proven track record in commercializing innovative therapies across multiple therapeutic areas with capabilities to launch sebetralstat in Canadian market CAMBRIDGE, Mass. & SALISBURY, England / Jun 26, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary,... Read More

Real-world data highlight significant challenges with LTP adherence, and ongoing reliance on on-demand medications In KONFIDENT-S, oral sebetralstat delivered rapid, consistent relief for breakthrough attacks, regardless of long-term prophylaxis mechanism of action CAMBRIDGE, Mass. & SALISBURY, England / Jun 16, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced the presentation of new data... Read More

FDA states heavy workload and limited resources prevent meeting PDUFA goal date of June 17 Agency indicates anticipated decision within four weeks CAMBRIDGE, Mass. & SALISBURY, England / Jun 13, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jun 05, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom from June 13–16, 2025. Details are as follows: Friday, June 13 Potential for Sebetralstat to Address Pseudo-allergic Reaction... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jun 03, 2025 / Business Wire / KalVista Pharmaceuticals, Inc . (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 50,000 shares of KalVista common stock on June 1, 2025 as inducements material to each employee entering into employment with KalVista. The... Read More

Attack progression halted in median 19.8 minutes after treatment with sebetralstat in both KONFIDENT and KONFIDENT-S trials Sebetralstat data demonstrated rapid relief and resolution of severe HAE attacks CAMBRIDGE, Mass. & SALISBURY, England / Jun 02, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced new sebetralstat findings related to time to end of progression of hereditary angioedema... Read More

CAMBRIDGE, Mass. & SALISBURY, England / May 29, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 8:45 a.m. ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com . An audio archive will be available on KalVista’s... Read More

CAMBRIDGE, Mass. & SALISBURY, England / May 22, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced that it will present new sebetralstat data at two upcoming congresses taking place concurrently from May 29–June 1, 2025: the 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida. The presentations will include... Read More

CAMBRIDGE, Mass. & SALISBURY, England / May 02, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Apr 30, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 11:30 a.m. ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com . An audio archive will be available on KalVista’s website... Read More

Up to $24 million in upfront and milestone payments, plus royalties Sebetralstat has potential to become first, oral on-demand treatment of HAE in Japan, underscoring commercial opportunity Kaken brings regional expertise and proven track record in commercializing innovative therapies CAMBRIDGE, Mass. & SALISBURY, England / Apr 08, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Apr 02, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 87,000 shares of KalVista common stock on April 1, 2025 as inducements material to each employee entering into employment with KalVista. The options... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Mar 31, 2025 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the 24 th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025 at 1:30 p.m. ET. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com . An audio archive will be available on... Read More

Initial target enrollment surpassed in fewer than seven months; trial expanded due to high demand First data presentation expected before year-end; sNDA submission by mid-2026 CAMBRIDGE, Mass. & SALISBURY, England / Mar 25, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an investigational, novel,... Read More

Announced seventh regulatory application submission and secured orphan drug designation for sebetralstat in Japan for hereditary angioedema Presented new data that showed effectiveness of sebetralstat to address critical unmet needs in laryngeal attacks, adolescents with HAE and patients experiencing attacks despite long-term prophylaxis (LTP) Will host virtual investor day to discuss commercialization strategy ahead of June... Read More

Webcast scheduled for Tuesday, March 25 at 8:00 am ET CAMBRIDGE, Mass. & SALISBURY, England / Mar 10, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced that it will host a virtual event to provide an overview of the commercialization strategy, plans and progress for sebetralstat, the Company’s investigational treatment for hereditary angioedema (HAE). The event will take place on Tuesday,... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Mar 04, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on March 3, 2025 as inducements material to each employee entering into employment with KalVista. The options... Read More

Sebetralstat enabled prompt treatment of laryngeal HAE attacks with median time of 1 hour and 16 minutes to onset of symptom relief Pooled data analysis showed adolescents treated with sebetralstat in median 4 minutes compared to over 3 hours in surveys CAMBRIDGE, Mass. & SALISBURY, England / Mar 03, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 24, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 1:10 p.m. ET in Boston, MA Leerink Partners 2025 Global Healthcare Conference on Monday, March 10, 2025, at 8:00 a.m. ET... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 21, 2025 / Business Wire / KalVista Pharmaceuticals , Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy Organization (WAO) 2025 Joint Congress taking place in San Diego, CA from February 28–March 3, 2025. The following poster presentations will take place on... Read More

Claims data show 40% of patients on long-term prophylaxis have gaps in prescription refills, leading to greater on-demand use and higher rate of LTP discontinuation Data from KONFIDENT-S show patients on LTP average 1.7 HAE attacks per month and symptom relief for treated attacks in median 1.3 hours Results confirm sebetralstat effective for on-demand treatment of attacks regardless of type of LTP therapy used, including an... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 04, 2025 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted fifty-two newly-hired employees inducement options to purchase an aggregate of 261,000 shares of KalVista common stock on February 3, 2025 as inducements material to each employee entering into employment with KalVista.... Read More

Orphan drug designation paves the way for potential of sebetralstat to be first oral on-demand treatment for HAE in Japan Submission advances Company’s strategic plan to address unmet needs in HAE on global scale CAMBRIDGE, Mass. & SALISBURY, England / Jan 21, 2025 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Dec 16, 2024 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the biotechnology industry. “I am pleased to welcome Jeb to KalVista at this key time in... Read More

Continuing to build commercial infrastructure; on track for potential sebetralstat launch in Q2 2025 Multinational regulatory submissions for sebetralstat position Company to transform hereditary angioedema (HAE) treatment worldwide Pro forma cash and cash equivalents of $292.2 million provide runway into second half 2027 CAMBRIDGE, Mass. & SALISBURY, England / Dec 05, 2024 / Business Wire / KalVista Pharmaceuticals, Inc.... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Dec 04, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 36,000 shares of KalVista common stock on December 2, 2024 as inducements material to each employee entering into employment with KalVista. The... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Nov 26, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of leadership and company-building success. “I am pleased to welcome Dr. Reid, with his deep expertise in... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Nov 12, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 9:10 a.m. EST Jefferies London Healthcare Conference on Thursday, November 21, 2024, at 11:00 a.m. GMT Each presentation will... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Nov 05, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 78,000 shares of KalVista common stock on November 1, 2024 as inducements material to each employee entering into employment with KalVista. The... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Nov 04, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share to certain investors (the “Offering”). The gross proceeds to KalVista from the Offering are expected to be $55 million, before deducting underwriting discounts,... Read More

Provides up to $184 million investment to support commercial launch of sebetralstat which, if approved, will be the first and only oral on-demand therapy for HAE Strengthens financial position as KalVista establishes global footprint for expected launches in multiple geographies in 2025 CAMBRIDGE, Mass. & SALISBURY, England / Nov 04, 2024 / Business Wire / KalVista Pharmaceuticals , Inc. (NASDAQ: KALV) (“KalVista”), today... Read More

Phase 3 trial data show that early treatment is correlated with shorter attack duration Rigorous comparison of Phase 3 results for oral sebetralstat and pivotal trial results of IV recombinant C1-inhibitor for on-demand treatment of HAE attacks shows no differences in time to beginning of symptom relief CAMBRIDGE, Mass. & SALISBURY, England / Oct 28, 2024 / Business Wire / KalVista Pharmaceuticals , Inc. (NASDAQ: KALV),... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Oct 18, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that five abstracts have been accepted for e-Poster presentation at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking place in Boston, MA from October 24-28. Presentations include: Patient-Reported Anxiety Impacts Utilization of... Read More

New data show effectiveness of sebetralstat in reducing anxiety during attacks; supports need for oral on-demand option to treat attacks earlier and more often Patient perspectives spotlight the prevalence of anxiety when faced with administering injectable on-demand therapies CAMBRIDGE, Mass. & SALISBURY, England / Oct 04, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Oct 02, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 31,000 shares of KalVista common stock on October 1, 2024 as inducements material to each employee entering into employment with KalVista. The... Read More

Submissions support KalVista’s mission of building a global footprint for sebetralstat to address the significant unmet need for people with HAE worldwide If approved, sebetralstat will be the first, oral on-demand treatment for HAE CAMBRIDGE, Mass. & SALISBURY, England / Sep 30, 2024 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV) today announced Marketing Authorization Application (MAA) submissions to the... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Sep 26, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the acceptance of multiple abstracts at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark October 4-5, 2024. The following nine abstracts have been accepted for poster presentation on Friday, October 4 between 6:00-7:00pm CET: Impact of Oral Sebetralstat on Anxiety... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Sep 10, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that its management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19th, 2024 at 10:20 a.m. ET in New York, N.Y. A live webcast of the presentation will be available on the Company’s website at www.kalvista.com . An audio archive will... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Sep 10, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the biotechnology sector. “Brian’s deep industry experience and expertise in managing... Read More

Patient perspectives shed additional light on the challenges of treating hereditary angioedema attacks with injectable on-demand therapies New analyses of sebetralstat clinical trials bolster efficacy and safety profile CAMBRIDGE, Mass. & SALISBURY, England / Sep 06, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented additional analyses of the efficacy and safety of... Read More

U.S. FDA accepts NDA for sebetralstat for oral on-demand treatment of HAE; Sets PDUFA goal date of June 17, 2025 European Medicines Agency (EMA) validated the submission of Marketing Authorization Application (MAA) for sebetralstat CAMBRIDGE, Mass. & SALISBURY, England / Sep 05, 2024 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today provided an operational update and released financial results for the... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Sep 04, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 55,000 shares of KalVista common stock on September 3, 2024 as inducements material to each employee entering into employment with KalVista. The... Read More

If approved, sebetralstat will be the first, oral on-demand treatment for HAE FDA PDUFA goal date of June 17, 2025 CAMBRIDGE, Mass. & SALISBURY, England / Sep 03, 2024 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Aug 29, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the acceptance of multiple abstracts at the 2024 Bradykinin Symposium taking place in Berlin, Germany September 5-6, 2024. The following presentations will take place on Friday, September 6 in the Kaiserin Friedrich-Haus Lecture Hall: Oral Presentations Delayed On-demand Treatment of... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Aug 15, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the European Medicines Agency (EMA) has validated the submission of a Marketing Authorization Application (MAA) for sebetralstat, a novel, investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE). This application will now be reviewed by... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Aug 02, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted eleven newly-hired employees inducement options to purchase an aggregate of 90,000 shares of KalVista common stock on August 1, 2024 as inducements material to each employee entering into employment with KalVista. The... Read More

Submitted NDA for sebetralstat as first-ever, oral on-demand treatment for HAE attacks, a pivotal moment for the HAE community Potential FDA approval and launch of sebetralstat in first half 2025 CAMBRIDGE, Mass. & SALISBURY, England / Jul 11, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2024.... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jul 02, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted twelve newly-hired employees inducement options to purchase an aggregate of 84,000 shares of KalVista common stock on July 1, 2024 as inducements material to each employee entering into employment with KalVista. The... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jun 27, 2024 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced the initiation of the open-label KONFIDENT-KID clinical trial of sebetralstat, a novel, oral, plasma kallikrein inhibitor, in pediatric patients with hereditary angioedema (HAE). The trial will enroll approximately 24 children aged 2 to 11 years across seven countries in North America, Europe... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jun 18, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the submission of a New Drug Application (NDA) for U.S. Food and Drug Administration (FDA) review of sebetralstat, a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and... Read More

US subgroup in the phase 3 KONFIDENT trial demonstrates median time to treatment of 38 minutes and time to beginning of symptom relief 1.3 hours Despite growing use of long-term prophylaxis therapies in the US on-demand treatment prescription volumes stay stable and non-prescription healthcare costs for management of HAE remain substantial CAMBRIDGE, Mass. & SALISBURY, England / Jun 06, 2024 / Business Wire / KalVista... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jun 04, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on June 3, 2024 as inducement material to such employee entering into employment with KalVista. The options... Read More

Patient perspectives reveal the challenges of injecting on-demand therapies and the consequences of delayed or withheld treatment Physicians characterize breakthrough HAE attacks occurring in patients receiving non-androgen long-term prophylaxis CAMBRIDGE, Mass. & SALISBURY, England / Jun 03, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented real-world data from US... Read More

Late-breaking data from phase 3 KONFIDENT trial of sebetralstat published in NEJM and presented concurrently at the European Academy of Allergy and Clinical Immunology Congress 2024 Interim data from KONFIDENT-S open-label trial show median time to treatment of 9 minutes and median time to beginning of symptom relief for laryngeal attacks 1.3 hours CAMBRIDGE, Mass. & SALISBURY, England / May 31, 2024 / Business Wire /... Read More

Late-breaking presentations for sebetralstat phase 3 KONFIDENT and KONFIDENT-S trials on Friday, May 31 Multiple real-world data presentations show that delay of injectable on-demand treatment for HAE attacks remains common CAMBRIDGE, Mass. & SALISBURY, England / May 24, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the acceptance of multiple abstracts and a symposium at the European... Read More

CAMBRIDGE, Mass. & SALISBURY, England / May 21, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management will participate in fireside chats at the following upcoming conferences: Stifel 2024 Tailoring Genes: Genetic Medicines Forum –... Read More

CAMBRIDGE, Mass. & SALISBURY, England / May 02, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 94,000 shares of KalVista common stock on May 1, 2024 as inducements material to each employee entering into employment with KalVista. The options... Read More

Regulatory filings planned for US, EU, UK and Japan to enable multiple 2025 commercial launches Development strategy refined for oral Factor XIIa program Organizational focus to drive results and set path to positive cash flow CAMBRIDGE, Mass. & SALISBURY, England / May 01, 2024 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced its strategic plans for fiscal year 2025, beginning May 1,... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Apr 22, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company’s Board of Directors, effective immediately. Mr. Fairey was most recently the Chief... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Apr 03, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management will participate in a fireside chat at the 23 rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 10:15... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Apr 02, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 65,000 shares of KalVista common stock on April 1, 2024 as inducements material to each employee entering into employment with KalVista. The... Read More

Delays in treating attacks lead to increased anxiety, quality of life issues, higher frequency of returning attacks, and suboptimal clinical outcomes in both on-demand and prophylaxis patients CAMBRIDGE, Mass. & SALISBURY, England / Mar 18, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small... Read More

Full EAMS designation would allow treatment of patients with sebetralstat prior to receiving a Marketing Authorization from UK CAMBRIDGE, Mass. & SALISBURY, England / Mar 12, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the UK Medicines and... Read More

Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema CEO transition supports ongoing evolution into commercial company - CAMBRIDGE, Mass. & SALISBURY, England / Mar 11, 2024 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery,... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Mar 08, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 HAEi Regional Conference meeting taking place in Panama City, Panama from March 15-17. KalVista is... Read More

Planned transition reflects evolution to commercial company with sebetralstat for HAE NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024 CAMBRIDGE, Mass. & SALISBURY, England / Mar 07, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors,... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Mar 06, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that its management will participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on Tuesday, March 12th, 2024 at... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Mar 04, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted seven newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on March 1, 2024 as inducements material to each employee entering into employment with KalVista. The... Read More

Patient perspectives revealed frequent treatment delays, suboptimal clinical outcomes and substantial anxiety associated with injectable on-demand treatments, including those who received long-term prophylaxis CAMBRIDGE, Mass. & SALISBURY, England / Feb 27, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization... Read More

94% of attacks required only one dose to achieve primary endpoint Further analyses demonstrate efficacy across all levels of attack severity Additional safety data reinforces flexibility of dosing CAMBRIDGE, Mass. & SALISBURY, England / Feb 26, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral,... Read More

Provides entry to UK Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines Late-breaking sebetralstat phase 3 data to be presented at the upcoming 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting CAMBRIDGE, Mass. & SALISBURY, England / Feb 20, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a... Read More

Late-breaking phase 3 data for KONFIDENT trial on Sunday, February 25, 2024 CAMBRIDGE, Mass. & SALISBURY, England / Feb 16, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2024 American Academy of... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 15, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common stock in lieu of KalVista common stock to certain investors. The gross... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 14, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) announced today that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering. In addition, KalVista intends to grant the underwriters a 30-day option... Read More

Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours Safety profile comparable to placebo On track for submission of new drug application to U.S. FDA in the first half of 2024 Conference call to discuss trial results today at 8:30 a.m. ET CAMBRIDGE, Mass. & SALISBURY, England / Feb 13, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 02, 2024 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 42,000 shares of KalVista common stock on February 1, 2024 as inducements material to each employee entering into employment with KalVista. The... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Dec 20, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that data from the first report of an oral, potent, and selective FXIIa inhibitor has been published in the peer-reviewed scientific journal,... Read More

Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Targeted Number of Attacks to Complete Trial Data Readout on Track for Early 2024; NDA Filing Expected H1 2024 CAMBRIDGE, Mass. & SALISBURY, England / Dec 07, 2023 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Dec 05, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on December 1, 2023 as inducements material to each employee entering into employment with KalVista. The... Read More

Patient perspectives on challenges with currently available parenteral on-demand HAE treatments explain basis for non-compliance with treatment guidelines Global prevalence of normal C1-inhibitor HAE (HAE-nC1-INH) may be greater than previously realized CAMBRIDGE, Mass. & SALISBURY, England / Nov 14, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the... Read More

Study completion activities underway; topline data expected early 2024 Largest-ever HAE clinical trial meets on-treatment attack target NDA submission remains on track for first half 2024 CAMBRIDGE, Mass. & SALISBURY, England / Nov 13, 2023 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Nov 07, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the following investor conferences: Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Nov 03, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted eight newly-hired employees inducement options to purchase an aggregate of 77,000 shares of KalVista common stock on November 1, 2023 as inducements material to each employee entering into employment with KalVista. The... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Nov 02, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), taking... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Oct 24, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the presentation of a novel analysis characterizing hereditary angioedema (HAE) attacks occurring in patients receiving long-term prophylaxis (LTP)... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Oct 03, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 103,000 shares of KalVista common stock on October 2, 2023 as inducements material to each employee entering into employment with KalVista. The... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Sep 19, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present at the Cantor Global Healthcare Conference on Wednesday, September 27th, 2023 at 4:10 p.m. ET in New York, NY. A live webcast of the... Read More

Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout on Track for Q4 Preparations Continue for NDA filing H1 2024 and Rapid Commercialization Upon Approval CAMBRIDGE, Mass. & SALISBURY, England / Sep 07, 2023 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Aug 28, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting taking place in Munich, Germany from September 1-3. KalVista... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Aug 02, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the grant of an inducement award to the Company’s recently appointed Chief Commercial Officer, Nicole Sweeny. In connection with Ms. Sweeny’s appointment, the compensation committee of KalVista’s board of directors granted inducement options to purchase an aggregate of 100,000 shares of... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jul 25, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, announced today the appointment of Nicole Sweeny as Chief... Read More

Real-world data show people with HAE consistently recognize onset of attacks and understand the need for early attack treatment - When provided similar efficacy and safety profiles for oral and injectable on-demand treatments for HAE attacks, adults and adolescents express a strong preference for oral on-demand treatment CAMBRIDGE, Mass. & SALISBURY, England / Jul 24, 2023 / Business Wire / KalVista Pharmaceuticals, Inc.... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jul 14, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 US HAEA National Summit taking place in Orlando, Florida from July 20-23. KalVista is a... Read More

Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout Expected in Q4 Company Funded Into 2025 With NDA Planned for H1 2024 CAMBRIDGE, Mass. & SALISBURY, England / Jul 07, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jul 05, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 13,000 shares of KalVista common stock on July 3, 2023 as inducements material to each employee entering into employment with KalVista. The options... Read More

Sebetralstat pharmacokinetic and pharmacodynamic data support globalization of the KONFIDENT phase 3 clinical trial and use in short-term prophylaxis Real-world patient data show significant burden from HAE still remains on patients receiving modern long-term prophylaxis and challenges associated with treatment decisions CAMBRIDGE, Mass. & SALISBURY, England / Jun 12, 2023 / Business Wire / KalVista Pharmaceuticals, Inc.... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jun 05, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate of 40,000 shares of KalVista common stock on June 1, 2023 as inducements material to each employee entering into employment with KalVista. The... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Jun 02, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 European Academy of Allergy and Clinical Immunology (EAACI) Congress, taking place in Hamburg,... Read More

CAMBRIDGE, Mass. & SALISBURY, England / May 31, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7th, 2023 at 2:00 p.m. ET in New York, NY. A live webcast of the... Read More

CAMBRIDGE, Mass. & SALISBURY, England / May 23, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the Stifel 2023 Tailoring Genes: Genetic Medicines Day virtual conference on Tuesday, May 30, 2023 at... Read More

Phase 1 data provide rationale for sebetralstat as short-term prophylaxis for medical and dental procedures Patient survey data demonstrate treatment burden associated with injectable on-demand treatments for HAE CAMBRIDGE, Mass. & SALISBURY, England / May 08, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and... Read More

CAMBRIDGE, Mass. & SALISBURY, England / May 02, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of KalVista common stock on May 1, 2023 as inducement material to such employee entering into employment with KalVista. The options were... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Apr 27, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 13th C1-inhibitor Deficiency & Angioedema Workshop taking place in Budapest, Hungary from May 4-7. The... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Apr 12, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Thursday, April 20, 2023 at 11:00 a.m. ET. A... Read More

CAMBRIDGE, Mass. & SALISBURY, United Kingdom / Mar 09, 2023 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2023. “We have made significant advances... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 27, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented five posters at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. The following presentations... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 16, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting for the American Academy of Allergy, Asthma & Immunology taking place in... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 14, 2023 / Business Wire / KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided multiple clinical trial and regulatory updates for its lead compound sebetralstat, as a potential oral on-demand therapy for HAE attacks. Clinical... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 10, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from the phase 2 trial evaluating the efficacy and safety of oral sebetralstat for the on-demand treatment of hereditary angioedema... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 07, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented three posters at the Western Society of Allergy, Asthma & Immunology 60th Annual Scientific Session in Kona, HI. The first highlighted that... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 03, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be presenting at the SVB Securities Global Biopharma Conference (virtual) on Thursday, February 16, 2023 at 8:40 a.m. ET. A live webcast of... Read More

CAMBRIDGE, Mass. & SALISBURY, England / Feb 02, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on February 1, 2023 as inducements material to each employee entering into employment with KalVista. The... Read More

Expanded role to lead business and commercial growth Follows $58 million financing in December 2022 led by top-tier syndicate KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the promotion of Ben Palleiko, the Company’s current Chief Business Officer and Chief... Read More

KalVista Pharmaceuticals, Inc. ( NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 1,000 shares of KalVista common stock on January 3, 2023 as inducement material to such employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The... Read More

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it has entered into a subscription agreement with institutional investors to sell, in a registered direct offering, an aggregate of 9.484 million shares of common stock at a price of $6.00 per share and 182,470... Read More